Drug Profile
ZD 3980
Latest Information Update: 07 Apr 1999
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antiandrogens
- Mechanism of Action Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 14 Sep 1998 Discontinued-Preclinical for Benign prostatic hyperplasia in United Kingdom (Unknown route)
- 12 Dec 1997 New profile